OTYŁOŚĆ - PRZYCZYNY I LECZENIE

Zofia Suchocka

doi:10.56782/pps.40

Published : 2003-08-04

Vol. 1 No. 1 (2003)

OBESITY - REASONS AND TREATMENT

Zofia Suchocka

DOI: https://doi.org/10.56782/pps.40

Abstract

Obesity is a chronic disease with a strong familial component, fostered by environment: lack of physical activity combined with high-calorie, low-cost foods. The recent increase in the incidence of obesity has been too sudden to be solely due to genetic factors. Epidemiological studies suggest that children born with poor maternal poor fetal nutrition resulted in increased rates of obesity later in life. Altered genetic expression as a consequence of an adaptation to changes during fetal development is a reason of profound adult hyperphagia. Programmed offspring also develop obesity, hyperleptynemia, hyperinsulinism and hypertension during adult life and postnatal hypercaloric nutrition amplifies the metabolic abnormalities induced by programming. Obesity and related metabolic disorders (diabetes mellitus, certain types of cancers, cardiovascular disease) have become a major health issue in modern society. Intra-abdominal fat accumulation in adult obese patients has been proposed as a risk factor for various biochemical disorders, which usually display a fatal course. Thus, the main prognostic problem in obesity is to estimate accurately the quantity and distribution of fat in the body. There are several different types of effective treatment options to manage weight including: dietary therapy, physical activity, behavior therapy, drug therapy, combined therapy and surgery. Weight loss of about 10 percent of excess body weight is proven to benefit health by reducing many obesity-related risk factors.

Keywords:

obesity, visceral obesity, pathophysiology of obesity, hyperphagia, obesity treatment

Similar Articles

Daria Żuraw, Paulina Oleksa, Mateusz Sobczyk, Kacper Jasiński, Simple obesity in children , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
Agnieszka Sienicka, Krzysztof Kubasik, Agata Pisula, The glucagon-like peptide-1 analogues therapy in the non-diabetic patients , Prospects in Pharmaceutical Sciences: Vol. 21 No. 1 (2023)
Magdalena Makarewicz, Anna Łysiak, Katarzyna Łysiak, Barbara Maziarz, Evaluation of the effectiveness of platelet-rich plasma therapy in the treatment of osteoarthritis compared to other treatment methods , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Michał Dacka, Mateusz Sobczyk , Paulina Dąbrowska , Kamila Giżewska , Michał Żuber , Role of calcitonin gene-related peptide (CGRP) receptor antagonist in acute and preventive treatment of migraine , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Katarzyna Kozon, Małgorzata Krzyżanowska, Jakub Olszewski, Andrzej Patyra, Spinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
Jakub Olszewski, Katarzyna Kozon, Magdalena Sitnik, Katarzyna Herjan, Karolina Mikołap, Bartłomiej Gastoł, Maciej Bara, Piotr Armański, Marcin Sawczuk, Mirikizumab – a new option in the treatment of inflammatory bowel diseases , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Aleksandra Ziółkowska, Szymon Wojtaszek, Bogdan Fels, Unraveling the weight of emotions: a comprehensive review of the interplay between depression and obesity , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Ewelina Flegiel, Magdalena Piotrowska, Magdalena Ptasznik, Aleksandra Baran, Justyna Lenart, Miłosz Podrażka, Joanna Mazurek, Hubert Stachowicz, Weronika Bartos, Monika Adamczyk, Review of the effects of sodium butyrate on obesity, inflammatory bowel disease, pregnancy and colorectal cancer , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Agnieszka Lembas, Andrzej Załęski, Tomasz Mikuła, Joanna Jabłońska, Szymon Barczak, Barbara Badura, Alicja Wiercińska-Drapało, Differences in the course of hepatocellular carcinoma depending on the DAA treatment , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Aleksandra Mikulska, Arkadiusz Kocur, Pharmacotherapy with high doses of methotrexate (HDMTX) in oncology – how should chemotherapy be conducted based on therapeutic drug monitoring? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 4 (2023)

1 2 3 4 5 6 7 8 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Suchocka, Z. (2003). OBESITY - REASONS AND TREATMENT. Prospects in Pharmaceutical Sciences, 1(1), 1–10. https://doi.org/10.56782/pps.40

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Schonfeld - Warden N., Warden Ch.: Pediatric obesity. An overview of etiology and treatment. Pediatr Clin North Am 1997; 44: 339 - 361. DOI: https://doi.org/10.1016/S0031-3955(05)70480-6

Troiano R.P., Flegal K.M., Kuczmarski R.J., Campbell S.M. Johnson CL.: Overweight prevalence and trends for children and adolescent. The National Health and Nutrition Examination Surveys 1963-1991, Arch Pediatr Adolesc Med 1995; 149, 1085-1091.

Serdula M.K., Irvey D., Coates R.J., Freedman D.S., Williamson D.S., Williamson D.F., Bayers T.: Do obese children become obese adults? A review of literature, Prev Med 1999; 22: 167-77. DOI: https://doi.org/10.1006/pmed.1993.1014

Kłosiewicz - Latoszek L., Pachocka L., Maliszewska K., Grzybek A., Murakowska E., Targosz U., Nowicka G.: Czynniki ryzyka choroby niedokrwiennej serca towarzyszące otyłości. Czynniki Ryzyka 1996; 11: 32 - 37.

Vanhala M.J., Pitkajarvi T.K., Kumpusalo E.A., Tokala J.K.: Obesity type and clustering of insulin resistance- associated cardiovascular risk faktors, in middle- aged men and women. Int J Obes Relat Metab Disord 1998; 22: 369 - 374. DOI: https://doi.org/10.1038/sj.ijo.0800597

Juhan-Vague I., Vague P.: Hypofibrinolisys and insulin - resistance. Diabet Metab 1991; 17: 96 - 100.

Czech A., Bernas M., Tatoń J.: Patofizjologiczne podstawy przechodzenia otyłości w cukrzycę typu II. Pol. Tyg. Lek. 1995; Supl 1: 37 - 41.

Cybulska B., Szostak W.B.: Otyłość wisceralna jako czynnik zagrożenia chorobą niedokrwienną serca. Pol. Tyg. Lek. 1995; Supl 1: 43 - 47.

Kielar D.: Molekularne podłoże etiopatogenezy otyłości (cz. I). Czynniki Ryzyka 1995; 9-10: 49 - 54.

Wójcicki J.: Otyłość - jej wpływ na dystrybucję, biotransformację i eliminację leków z organizmu. Czynniki Ryzyka 1994; 3: 18 - 25.

Basedevant A., Le Barzic M., Guy-Grand B.: Otyłość. Medycyna praktyczna. PZWL, Kraków 1993; 25 - 42.

Rywik S., Wągrowska H., Piotrowski W., Broda G.: Epidemiologia otyłości jako czynnika ryzyka chorób układu krążenia. Pol. Tyg. Lek. 1995; Supl 1 : 63 - 67.

Health implications of obesity. National Institutes of Health Consensus Development Conference Statement. Ann Intern Med 1985: 103;147- 151. DOI: https://doi.org/10.7326/0003-4819-103-1-147

Szmatłoch E.: Współistnienie metabolicznych i innych czynników zagrożenia miażdżycą w otyłości. Pol. Tyg. Lek. 1995; Supl 1 : 41 - 42.

Kielar D.: Molekularne podłoże etiopatogenezy otyłości ( cz. II). Czynniki Ryzyka 1995; 11: 26 31.

Basedevant A., Le Barzic M., Guy-Grand B.: Otyłość. Medycyna praktyczna. PZWL, Kraków 1993; 25 - 42.

Bjorntorp P.: Trifty genes and human obesity. Are we chasing ghosts? Lancet 2000; 358, 1006-1008. DOI: https://doi.org/10.1016/S0140-6736(01)06110-4

Breier B.H., Vicker M.H., Ikenasio B.A., Chan K.Y., Wong W.P.S: Fetal programing of appetite and obesity. Mol. Cell. Endocrinol. 2001; 185, 73-79. DOI: https://doi.org/10.1016/S0303-7207(01)00634-7

Świerczyński J., Kochan Z., Karbowska J.: Geny otyłości. Post. Bioch.1997; 43: 174 - 182.

Sakata T.: Histamine receptor and its regulation of energy metabolism. Obes Res 1995; 3 Supl 4: 541 - 548 DOI: https://doi.org/10.1002/j.1550-8528.1995.tb00225.x

Clement K., Vaisse C., Manning B.S., Basdevant A., Guy-Grand B., Ruiz J., Silver K.D., Shuldiner A.R., Froguel P., Strosberg A.D.: Genetic variation in the b3- adrenergic receptor and an increased capacity to gain weigh in patients with morbid obesity. N. Engl. J. Med. 1995; 333: 352 - 354. DOI: https://doi.org/10.1056/NEJM199508103330605

Walston J., Silver K., Bodardus C.: Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the b3- adrenergic receptor gene. N. Engl. J. Med. 1995; 333: 343 - 347. DOI: https://doi.org/10.1056/NEJM199508103330603

Baranowska B.: Zaburzenia neuroendokrynne w otyłości. Pol. Tyg. Lek. 1995; Supl 1: 26 28.

Vanderschneren - Lodeweyckx M.: The effect of simple obesity on growth and growth hormone. Horm Res 1993; 40: 23 - 30. DOI: https://doi.org/10.1159/000183763

Gutin B., Manos T.M.: Physical Activity in the Prevention of Childhood Obesity. Ann NY Acad Sci 1993; 699: 115 1. DOI: https://doi.org/10.1111/j.1749-6632.1993.tb18843.x

Nazar K., Kaciuba - Uściłko H.: Aktywność ruchowa w zapobieganiu i leczeniu otyłości. Pol. Tyg. Lek. 1995; Supl 1: 68 - 69.

Levin B.E.: Metabolic impriting on genetically Predisposed Neural Circuits Perpetuates Obesity. Nutrition 2000; 16:909-915. DOI: https://doi.org/10.1016/S0899-9007(00)00408-1

Białkowska M.:Otyłość wisceralna - diagnostyka, przyczyny, skutki. Czynniki Ryzyka 1994; 3: 34 - 40.

Poskitt E.: Defining childhood obesity: the relative body mass index (BMI). Acta Paediatr 1995, 84:961-2. DOI: https://doi.org/10.1111/j.1651-2227.1995.tb13806.x

Siatka percentylowa BMI: Palczewska I., Niedźwiecka Z., Instytut Matki i Dziecka, Warszawa 1999.

Komorowski J., Pawlikowski M.: Otyłość i jadłowstręt psychczny. w: Zarys Endokrynologii Klinicznej., Ed.: Komorowski J., Pawlikowski M., PZWL, Warszawa 1992; 223 229].

Dokument WHO. Measuring obesity- classification and description of anthropometric data. Copenhagen,WHO Regional Office for Europe Nutrition Unit EUR/ICP/NUT. 1988;125

Tatoń J.: Związki między otyłością i cukrzycą typu 2. Pol Tyg Lek 1995; Supl 1 :56-62.

Troiano R.P., Flegal K.M., Kuczmarski R.J., Campbell S.M., Johnson C.L.: Overweight prevalence and trends for children and adolescent. The National Health and Nutrition Examinations Surveys 1963-1991. Arch Pediatr Adolesc Med 1995;149: 1085-1091. DOI: https://doi.org/10.1001/archpedi.1995.02170230039005

Caroli M., Lagravinese D.: Prevention of obesity. Nutr Res 2002; 22: 221-226. DOI: https://doi.org/10.1016/S0271-5317(01)00364-5

OBESITY - REASONS AND TREATMENT

Zofia Suchocka

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Zofia Suchocka